FY2026 · period end Jun '26 · from the 10-K filed Aug 14, 2026
Data as filed with the SEC, provided for information only — not investment advice.
| Metric | FY26Jun '26 | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 |
|---|---|---|---|---|---|
| Revenue | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B |
| Gross Profit | $3.45B | $3.05B | $2.66B | $2.36B | $2.02B |
| Operating Income | $1.89B | $1.69B | $1.32B | $1.13B | $1.00B |
| Net Income | $1.52B | $1.40B | $1.02B | $0.90B | $0.78B |
| EPS (Diluted) | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 |
| Metric | FY26Jun '26 | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 |
|---|---|---|---|---|---|
| Total Assets | $8.97B | $8.17B | $6.87B | $6.75B | $5.10B |
| Total Liabilities | $2.38B | $2.21B | $2.01B | $2.62B | $1.74B |
| Stockholders' Equity | $6.59B | $5.97B | $4.86B | $4.13B | $3.36B |
| Cash & Equivalents | $1.47B | $1.21B | $0.24B | $0.23B | $0.27B |
| Total Debt | — | — | — | — | — |
| Metric | FY26Jun '26 | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.81B | $1.75B | $1.40B | $0.69B | $0.35B |
| Capital Expenditures | $0.16B | $0.09B | $0.10B | $0.12B | $0.13B |
| Free Cash Flow | $1.65B | $1.66B | $1.30B | $0.57B | $0.22B |
| Metric | FY26Jun '26 | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 |
|---|---|---|---|---|---|
| Gross Margin | 61.1% | 59.4% | 56.7% | 55.8% | 56.6% |
| Operating Margin | 33.4% | 0.3% | 0.3% | 0.3% | 0.3% |
| Net Margin | 26.9% | 0.3% | 0.2% | 0.2% | 0.2% |
| Return on Equity | 23.1% | 25.9% | 22.7% | 24.0% | 25.0% |
| Return on Assets | 17.0% | 18.6% | 15.0% | 15.2% | 15.9% |
| Debt / Equity | — | 0.00× | 0.00× | 0.00× | 0.00× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or full history back to 1993 plus the smart-money dataset and webhooks on Institutional.
Who is buying and selling RESMED INC — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on RMD yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on RMD and publish the result to your public profile.
Ask about RESMED INC
Continue in Workspace — cited answers on RMD, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate, with delisted companies kept in.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-K | 0000943819-26-000047 | Jun 30, 2026 | Aug 13, 2026 | Aug 14, 2026 01:17 UTC | EDGAR |
| 10-Q | 0000943819-26-000025 | Mar 31, 2026 | May 1, 2026 | May 1, 2026 02:19 UTC | EDGAR |
| 10-Q | 0000943819-26-000007 | Dec 31, 2025 | Jan 30, 2026 | Jan 30, 2026 00:37 UTC | EDGAR |
| 10-Q | 0000943819-25-000090 | Sep 30, 2025 | Oct 31, 2025 | Oct 31, 2025 00:01 UTC | EDGAR |
| 10-K | 0000943819-25-000035 | Jun 30, 2025 | Aug 8, 2025 | Aug 8, 2025 00:44 UTC | EDGAR |
| 10-Q | 0000943819-25-000008 | Mar 31, 2025 | Apr 24, 2025 | Apr 24, 2025 02:20 UTC | EDGAR |
| 10-Q | 0000943819-25-000004 | Dec 31, 2024 | Jan 31, 2025 | Jan 31, 2025 00:08 UTC | EDGAR |
| 10-Q | 0000943819-24-000027 | Sep 30, 2024 | Oct 25, 2024 | Oct 25, 2024 03:37 UTC | EDGAR |
| 10-K | 0000943819-24-000013 | Jun 30, 2024 | Aug 9, 2024 | Aug 9, 2024 00:09 UTC | EDGAR |
| 10-Q | 0000943819-24-000008 | Mar 31, 2024 | Apr 26, 2024 | Apr 26, 2024 03:18 UTC | EDGAR |
| 10-Q | 0000943819-24-000003 | Dec 31, 2023 | Jan 25, 2024 | Jan 25, 2024 00:50 UTC | EDGAR |
| 10-Q | 0000943819-23-000029 | Sep 30, 2023 | Oct 27, 2023 | Oct 27, 2023 03:38 UTC | EDGAR |
Direct links to SEC EDGAR. RMD has additional filings available on the SEC site.
6 numbers RESMED INC later changed — same XBRL tag, both filings linked.
Net Income (Loss) Attributable to Parent·Q2 2015
Notable restatementwas$90.5M
Revised up in a 10-Q. Any P/E built on the original was 5.3% too high.
Gross Profit·Q1 2019
Notable restatementwas$405.1M
Revised down in a 10-Q.
Net Income (Loss) Attributable to Parent·Q1 2015
Notable restatementwas$80.4M
Revised up in a 10-Q. Any P/E built on the original was 3.0% too high.
Gross Profit·Q3 2019
Notable restatementwas$391.9M
Revised down in a 10-Q.
Gross Profit·FY 2019
Notable restatementwas$1.5B
Revised down in a 10-K.
Net Income (Loss) Attributable to Parent·Q3 2016
Notable restatementwas$88.5M
Revised up in a 10-Q. Any P/E built on the original was 2.6% too high.
RMD is not the only one.
See every restatement we've found across the market — or get an alert the next time RMD revises a number.
Restatements are detected by comparing every vintage of a fact across all of RESMED INC's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows RMD's most significant revisions, and a figure absent from it has not been certified as unrevised.
